Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Johnson and Johnson
Moodys
Harvard Business School
McKesson

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

ZENPEP Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Zenpep patents expire, and when can generic versions of Zenpep launch?

Zenpep is a drug marketed by Forest Labs Inc and is included in one NDA. There are seven patents protecting this drug.

This drug has forty-two patent family members in twenty-seven countries.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

US ANDA Litigation and Generic Entry Outlook for Zenpep

Zenpep was eligible for patent challenges on August 27, 2013.

Annual sales in 2017 were $170mm indicating the motivation for generic entry (peak sales were $889mm in 2016).

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for ZENPEP
Drug patent expirations by year for ZENPEP
Drug Prices for ZENPEP

See drug prices for ZENPEP

Drug Sales Revenue Trends for ZENPEP

See drug sales revenues for ZENPEP

Recent Clinical Trials for ZENPEP

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AllerganPhase 2
Dana-Farber Cancer InstitutePhase 2
University of Colorado, DenverN/A

See all ZENPEP clinical trials

US Patents and Regulatory Information for ZENPEP

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Forest Labs Inc ZENPEP pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 022210-006 Jul 13, 2011 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Forest Labs Inc ZENPEP pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 022210-004 Aug 27, 2009 RX Yes No   Start Trial   Start Trial   Start Trial
Forest Labs Inc ZENPEP pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 022210-003 Aug 27, 2009 RX Yes No   Start Trial   Start Trial Y   Start Trial
Forest Labs Inc ZENPEP pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 022210-004 Aug 27, 2009 RX Yes No   Start Trial   Start Trial Y   Start Trial
Forest Labs Inc ZENPEP pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 022210-003 Aug 27, 2009 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Merck
AstraZeneca
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.